Rock Weekly: Like the letter of a jilted lover

December 2, 2013

Over turkey dinners last week, the conversation turned to genomics and the tech surge. There was no shortage of opinions on the FDA’s letter to 23andMe (“It reads like the letter of a jilted lover,” said Duke professor Misha Angrist, while Matthew Herper penned the harshly titled “23andStupid?“), amid claims that the FDA had not heard from the company since May.

Not everyone took Thanksgiving off, as developers for worked over the holiday to meet the November 30th promise that the site would be functional for the majority of users.  Yesterday, the Obama administration said that they met their deadline for significant improvements to the site and that it was “night and day from where it was on October 1st.”



The FDA vs. Personal Genetic Testing
The New Yorker

Inside the Race to Rescue a Health Care Site, and Obama
New York Times

Do Genetic Tests Need Doctors?
Bloomberg Businessweek

New CEO Sought

Pew Report: People Who Are Actually Sick Don’t Use High-Tech Health Tracking Devices

First Made-for-iPhone Hearing Aid Now Available

51 Digital Health Metrics in 2013
MobiHealthNews Files Confidentially for IPO Next Year
Boston Business Journal



Name Amt Investors Source
WellRight $4M Undisclosed Press release $2M Baird Capital, Arthur Ventures, Chicago Ventures SEC
Dabo Health $1.9M Undisclosed SEC
Rest Devices $1.3M Experiment Fund and angels Wall Street Journal

Get the Rock Weekly for news and funding in digital health!

    Rock Health will use the information you provide on this form to be in touch with you with news and occasional marketing.

    You can change your mind at any time by clicking the unsubscribe link at the bottom of our emails or by contacting We will treat your information with respect. By clicking below, you agree that we may process your info in accordance with these terms.